Sign in Subscribe
Cancer genetics

MicroRNA-17-5p: A Potential Therapeutic Target for Cancer and Beyond

Strategic Insights

— 1 min read

Fresh data on biotechnology and cancer gene therapy have shed light on the regulatory molecule microRNA-17-5p (miR-17-5p), which plays a pivotal role in various diseases, including cancer, inflammatory conditions, and genetic disorders such as cystic fibrosis. Research from the RCSI University of Medicine and Health Sciences has highlighted the potential of miR-17-5p as a biomarker and therapeutic target, offering hope for more personalized and effective treatments across multiple disease areas.

Key Takeaways:

  • MicroRNA-17-5p (miR-17-5p) is a regulatory molecule that plays a crucial role in various diseases, including cancer, inflammatory conditions, and genetic disorders such as cystic fibrosis.
  • miR-17-5p has pleiotropic functions across cancers, inflammatory conditions, and genetic disorders, such as cystic fibrosis, and its dysregulation is associated with disease progression and therapeutic resistance.
  • Recent advances in RNA delivery technologies, including nanocarriers, exosome-based systems, and receptor-targeted delivery platforms, have unlocked new possibilities for miR-17-5p modulation with enhanced precision and minimized off-target effects.
  • miR-17-5p has the potential to be used as a biomarker and therapeutic target, offering a path toward more personalized and effective treatments across multiple disease areas.
  • The research was conducted by a team of investigators from the RCSI University of Medicine and Health Sciences, including Yin He Richard Sun, Yunfei Ye, Irene K. Oglesby, Yiran Zheng, and Catherine M. Greene.
  • The study has been peer-reviewed and published in the journal Epigenomics.

Statistics:

  • 16 - The number of pages dedicated to the review of miR-17-5p in Epigenomics.
  • 1 - The volume in which the research is published.
  • 2025 - The year in which the research was published.
  • 1-16 - The page numbers of the publication.

Sources:

  • "miR-17-5p: bridging the gap between disease mechanisms and therapeutic innovations." Epigenomics, 2025:1-16.
  • Investigators at RCSI University of Medicine and Health Sciences Have Reported New Data on Cancer Gene Therapy (miR-17-5p: bridging the gap between disease mechanisms and therapeutic innovations). Cancer Weekly. October 21, 2025; p 37.

Read more